Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 3
2008 1
2009 5
2010 4
2011 3
2012 1
2013 6
2014 4
2015 6
2016 5
2017 8
2018 7
2019 8
2020 4
2021 7
2022 7
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean jin byung ho[Author] (28 results)?
PIBF1 regulates trophoblast syncytialization and promotes cardiovascular development.
Lee JG, Yon JM, Kim G, Lee SG, Kim CY, Cheong SA, Kim HY, Yu J, Kim K, Sung YH, Yoo HJ, Woo DC, Rho JK, Ha CH, Pack CG, Oh SH, Lim JS, Han YM, Hong EJ, Seong JK, Lee HW, Lee SW, Lee KU, Kim CJ, Nam SY, Cho YS, Baek IJ. Lee JG, et al. Among authors: rho jk. Nat Commun. 2024 Feb 19;15(1):1487. doi: 10.1038/s41467-024-45647-8. Nat Commun. 2024. PMID: 38374152 Free PMC article.
Retraction Note: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. Garofalo M, et al. Among authors: rho jk. Nat Med. 2022 Nov;28(11):2436. doi: 10.1038/s41591-022-02044-2. Nat Med. 2022. PMID: 36195688 Free PMC article. No abstract available.
Generation of genetically engineered mice for lung cancer with mutant EGFR.
Kim DS, Ji W, Kim DH, Choi YJ, Im K, Lee CW, Cho J, Min J, Woo DC, Choi CM, Lee JC, Sung YH, Rho JK. Kim DS, et al. Among authors: rho jk. Biochem Biophys Res Commun. 2022 Dec 3;632:85-91. doi: 10.1016/j.bbrc.2022.09.104. Epub 2022 Sep 30. Biochem Biophys Res Commun. 2022. PMID: 36206598
Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: rho jk. Cancer Res. 2022 Aug 26:OF1. doi: 10.1158/0008-5472.CAN-22-2507. Online ahead of print. Cancer Res. 2022. PMID: 36018295 No abstract available.
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
Choi YJ, Kim DS, Hoon Sung Y, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: rho jk. Cancer Res. 2022 Jun 14:canres.0394.2022-2-3 21:03:12.200. doi: 10.1158/0008-5472.CAN-22-0394. Online ahead of print. Cancer Res. 2022. PMID: 35700239 Retracted.
78 results